| 000 | 01901 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514072343.0 | ||
| 264 | 0 | _c20040128 | |
| 008 | 200401s 0 0 ger d | ||
| 022 | _a0340-1855 | ||
| 024 | 7 |
_a10.1007/s00393-003-0522-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrandt, J | |
| 245 | 0 | 0 |
_a[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]. _h[electronic resource] |
| 260 |
_bZeitschrift fur Rheumatologie _cJun 2003 |
||
| 300 |
_a264-73 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aActivities of Daily Living _xclassification |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aCross-Cultural Comparison |
| 650 | 0 | 4 | _aDisability Evaluation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGermany |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aLanguage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPain Measurement _xstatistics & numerical data |
| 650 | 0 | 4 |
_aPsychometrics _xstatistics & numerical data |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 |
_aSpondylarthropathies _xclassification |
| 650 | 0 | 4 |
_aSpondylitis, Ankylosing _xclassification |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aWesthoff, G | |
| 700 | 1 | _aRudwaleit, M | |
| 700 | 1 | _aListing, J | |
| 700 | 1 | _aZink, A | |
| 700 | 1 | _aBraun, J | |
| 700 | 1 | _aSieper, J | |
| 773 | 0 |
_tZeitschrift fur Rheumatologie _gvol. 62 _gno. 3 _gp. 264-73 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00393-003-0522-y _zAvailable from publisher's website |
| 999 |
_c12610352 _d12610352 |
||